As of the 3rd July 2012 there have been 264 confirmed cases of PML in MSers on natalizumab. The next 3 figures are an update of the latest the risks.
"The following is the monthly slide deck that Biogen-Idec provides the MS community. You may find some of the information in the deck interesting."
CoI: multiple and ongoing
Labels: Natalizumab, PML Risk update